Myriad Genetics stock trades at EUR 5.97 in late L&S snapshot

Myriad Genetics stock was quoted at 5.97 euros by Lang & Schwarz on October 29, 2026, at 10:59:30 p.m. Berlin time. The licensed market-data snapshot showed no change against its displayed previous close of 5.97 euros.

Quote offers a late-session reference

The quote is a late-session reference for the US-listed molecular diagnostics company rather than a statement about the next Nasdaq opening. The snapshot also showed a bid of 5.94 euros and an ask of 6.00 euros, indicating the displayed trading range around the quoted level.

For investors comparing venues, Barron's company page identified the Xetra listing as MYD and displayed a 5.92-euro quote at 1:17 p.m. CEST on October 29. That is a separate exchange quote and should not be treated as the Lang & Schwarz price.

Diagnostics remains the business focus

Barron's describes Myriad Genetics as a molecular diagnostics and precision medicine company. Its activities include developing and commercializing molecular tests designed to help patients and healthcare providers uncover genetic insights.

The same source places the company in health care and life sciences, with medical equipment and supplies as its industry. The quoted market data provide a current reference point, while company performance and valuation require separate consideration of financial results, test demand and the outlook for precision medicine.

The broader US market context can be followed in the S&P 500 coverage.

For further company-specific coverage, see the real-time quote of Myriad Genetics stock and more news and analyses on Myriad Genetics stock.